The introduction of the EU Health Technology Assessment (HTA) Regulation presents a unique opportunity for Europe to standardise clinical evaluations, enhance patient safety, and improve access to high-risk medical devices. This scoping review highlights the significant variations in how European countries currently integrate HTA into national reimbursement frameworks for high-risk medical devices, how the national decisions are implemented and how the uncertainty of evidence is assessed.